Castle Biosciences Inc (CSTL) Stock Analysis and Metrics

Castle Biosciences

NASDAQ: CSTL

$23.01 ▼ -0.71 (-2.99%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap738.56 Mn

P/E-57.56

P/S2.17

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)10.07 Mn

Revenue Growth (1y) (Qtr)-4.90

Add ratio to table…

About

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes proprietary gene expression profile and spatialomics tests to help clinicians diagnose and manage dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. The company’s core technology uses multi analyte assays with algorithmic analysis to convert tumor or tissue biology into clinically actionable risk scores. Founded in 2008, Castle Biosciences focuses on delivering personalized information that informs treatment decisions and aims to improve patient outcomes across its test portfolio.

Castle Biosciences generates revenue primarily from the sale of its diagnostic tests, which are billed to third party payors including Medicare, commercial insurers, and patients who self pay. Reimbursement amounts are determined by Medicare clinical laboratory fee schedule rates or negotiated contracts with commercial payors, and the company also receives payments from laboratory services intermediaries. The volume of test reports delivered drives top line growth, as demonstrated by increasing test counts and net revenues in recent fiscal years.

Within the molecular diagnostics arena, Castle Biosciences holds a differentiated position through its portfolio of proprietary tests that have earned Medicare coverage and Advanced Diagnostic Laboratory Test status from the Centers for Medicare & Medicaid Services. The company’s competitive advantages include its strong clinical evidence base, with over 150 peer reviewed publications supporting its tests, and its ability to secure reimbursement from governmental and commercial payors. Principal competitors vary by test: for DecisionDx‑Melanoma, traditional pathology staging criteria and emerging players such as SkylineDx represent the main alternatives; for TissueCypher, standard Barrett’s esophagus surveillance and companies like Interpace Diagnostics and Lucid Diagnostics are comparable; DecisionDx‑SCC faces conventional high‑risk squamous cell carcinoma criteria; DecisionDx‑UM competes with existing ocular melanoma assays offered by academic laboratories and a LabCorp subsidiary; and MyPath Melanoma contends with subjective histologic evaluation of ambiguous pigmented lesions. The company’s focus on algorithmic driven reports, broad payer coverage, and ongoing pipeline development underpins its market stance.

Castle Biosciences serves clinicians specializing in dermatology, gastroenterology, ophthalmology, and allergy/immunology who order its tests to guide treatment decisions for patients with melanoma, squamous cell carcinoma, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. The customer base includes community dermatology practices, academic medical centers, hospital based pathology laboratories, and gastroenterology clinics that send tissue or non invasive samples for analysis. While specific customer names are not disclosed in the filing, the company’s reimbursement data indicate a broad mix of Medicare beneficiaries and commercially insured individuals across the United States.

Investment Thesis

▲ Bull case

Castle Biosciences, Inc. is positioned for sustained long-term growth through the underappreciated scalability of its Advanced ADTx test in the atopic dermatitis market, which represents a significant structural shift beyond its core oncology and gastroenterology franchises. Despite limited initial access and only 650 orders in Q1 2026, the test has demonstrated strong clinical validation, showing patients with a JAK Inhibitor Responder Profile are 5.5 times more likely to achieve near-clear skin (EASI-90) and reach that response 3.8 times faster when treated with JAK inhibitors versus Th2-targeted therapies, according to the prospective multi-center study cited in the MedTech Breakthrough award announcement. This level of therapeutic differentiation addresses a critical unmet need in a market where patients routinely cycle through ineffective biologics due to lack of biomarker-driven guidance, creating a clear value proposition for payers and providers seeking to reduce treatment failure costs and improve quality of life. The company’s strategy to expand access gradually based on early RCM signals and reimbursement clarity by end of Q3 2026 suggests a deliberate, low-risk rollout that avoids premature commercialization while building real-world evidence. With the atopic dermatitis market encompassing millions of patients and current standard of care relying solely on clinical assessment, Advanced ADTx has the potential to become a multi-hundred-million-dollar revenue driver by 2028, far exceeding current investor expectations tied primarily to melanoma and TissueCypher growth. The recent MedTech Breakthrough Genomics Innovation Award further validates the test’s innovation and clinical utility, signaling third-party recognition that could accelerate adoption and payer engagement—factors management did not emphasize during the earnings call but which represent a hidden catalyst for future inflection in revenue mix and gross margin expansion as the test scales.
The company’s TissueCypher franchise is exhibiting stronger-than-acknowledged secular growth potential in the Barrett’s esophagus market, driven by irreversible clinical adoption trends that management attributed partially to seasonal volatility but which reflect deeper structural shifts in gastroenterology practice. While Q1 2026 showed a modest quarter-over-quarter decline in TissueCypher test reports—prompting questions about seasonality—the underlying year-over-year growth of 58% and the dual Mayo Clinic studies presented at Digestive Disease Week demonstrating changes in surveillance intervals in over half of patients compared to histopathology alone reveal a fundamental change in clinical decision-making. These studies show TissueCypher is not merely an add-on test but is actively replacing or refining standard of care by enabling risk-stratified, personalized management—reducing unnecessary procedures for low-risk patients while intensifying surveillance for high-risk individuals. Management’s expectation to add a similar number of tests in 2026 as in 2025, implying ~50% year-over-year growth, may be conservative given the accelerating clinical validation and the fact that March and April 2026 were all-time record months, with the trend continuing into April per Derek Maetzold’s comments. This suggests the business has penetrated deeply enough to exhibit true seasonality—a sign of maturation—and that the underlying demand trajectory remains robust. The gastroenterology franchise’s expansion beyond Barrett’s esophagus into other indications (implied by ongoing pipeline work) combined with increasing physician familiarity and reimbursement acceptance positions TissueCypher for durable, high-retention growth that is less vulnerable to cyclical fluctuations than management acknowledged, offering a more reliable and scalable revenue stream than current guidance implies.
Castle Biosciences, Inc. is building a fortress-like financial profile characterized by improving operational efficiency and a growing war chest that is being underestimated by the market, providing both downside protection and fuel for strategic acceleration. Despite reporting a GAAP net loss of $14.5 million in Q1 2026, the company generated $261.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026—a substantial liquidity buffer that exceeds one year of operating cash burn at the current run rate and provides ample runway to fund R&D, sales expansion, and potential M&A without dilutive financing. More importantly, the trajectory of key efficiency metrics is improving: Adjusted EBITDA loss narrowed from -$13.0 million in Q1 2025 to -$5.1 million in Q1 2026, driven by operating leverage as revenue grew 36% in core test volumes while total operating expenses decreased 11.8% year-over-year to $102.1 million. This improvement occurred despite increased investment in salesforce expansion (headcount growth supporting higher personnel costs in SG&A) and lab capacity (higher depreciation from facility investments), indicating that the business is successfully scaling without proportional cost inflation. The gross margin expansion from 49.2% in Q1 2025 to 72.8% in Q1 2026—despite lapping a one-time $20.1 million accelerated amortization benefit in the prior year—reflects genuine operational improvement in lab efficiency and scale, as evidenced by the stable adjusted gross margin of 75.6% (down only slightly from 81.2% in Q1 2025 due to higher variable costs from volume growth). This combination of rising margins, falling cash burn relative to revenue, and a strong balance sheet suggests the company is closer to sustainable profitability and cash flow positivity than current losses imply, with the potential to reinvest excess cash into high-return initiatives like Advanced ADTx commercialization or bolt-on acquisitions in adjacent diagnostic areas—moves that could significantly enhance long-term value creation beyond organic growth expectations.

Castle Biosciences, Inc. is positioned for sustained long-term growth through the underappreciated scalability of its Advanced ADTx test in the atopic dermatitis market, which represents a significant structural shift beyond its core oncology and gastroenterology franchises. Despite limited initial access and only 650 orders in Q1 2026, the test has demonstrated strong clinical validation, showing patients with a JAK Inhibitor Responder Profile are 5.5 times more likely to achieve near-clear skin (EASI-90) and reach that response 3.8 times faster when treated with JAK inhibitors versus Th2-targeted therapies, according to the prospective multi-center study cited in the MedTech Breakthrough award announcement. This level of therapeutic differentiation addresses a critical unmet need in a market where patients routinely cycle through ineffective biologics due to lack of biomarker-driven guidance, creating a clear value proposition for payers and providers seeking to reduce treatment failure costs and improve quality of life. The company’s strategy to expand access gradually based on early RCM signals and reimbursement clarity by end of Q3 2026 suggests a deliberate, low-risk rollout that avoids premature commercialization while building real-world evidence. With the atopic dermatitis market encompassing millions of patients and current standard of care relying solely on clinical assessment, Advanced ADTx has the potential to become a multi-hundred-million-dollar revenue driver by 2028, far exceeding current investor expectations tied primarily to melanoma and TissueCypher growth. The recent MedTech Breakthrough Genomics Innovation Award further validates the test’s innovation and clinical utility, signaling third-party recognition that could accelerate adoption and payer engagement—factors management did not emphasize during the earnings call but which represent a hidden catalyst for future inflection in revenue mix and gross margin expansion as the test scales.
The company’s TissueCypher franchise is exhibiting stronger-than-acknowledged secular growth potential in the Barrett’s esophagus market, driven by irreversible clinical adoption trends that management attributed partially to seasonal volatility but which reflect deeper structural shifts in gastroenterology practice. While Q1 2026 showed a modest quarter-over-quarter decline in TissueCypher test reports—prompting questions about seasonality—the underlying year-over-year growth of 58% and the dual Mayo Clinic studies presented at Digestive Disease Week demonstrating changes in surveillance intervals in over half of patients compared to histopathology alone reveal a fundamental change in clinical decision-making. These studies show TissueCypher is not merely an add-on test but is actively replacing or refining standard of care by enabling risk-stratified, personalized management—reducing unnecessary procedures for low-risk patients while intensifying surveillance for high-risk individuals. Management’s expectation to add a similar number of tests in 2026 as in 2025, implying ~50% year-over-year growth, may be conservative given the accelerating clinical validation and the fact that March and April 2026 were all-time record months, with the trend continuing into April per Derek Maetzold’s comments. This suggests the business has penetrated deeply enough to exhibit true seasonality—a sign of maturation—and that the underlying demand trajectory remains robust. The gastroenterology franchise’s expansion beyond Barrett’s esophagus into other indications (implied by ongoing pipeline work) combined with increasing physician familiarity and reimbursement acceptance positions TissueCypher for durable, high-retention growth that is less vulnerable to cyclical fluctuations than management acknowledged, offering a more reliable and scalable revenue stream than current guidance implies.
Castle Biosciences, Inc. is building a fortress-like financial profile characterized by improving operational efficiency and a growing war chest that is being underestimated by the market, providing both downside protection and fuel for strategic acceleration. Despite reporting a GAAP net loss of $14.5 million in Q1 2026, the company generated $261.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026—a substantial liquidity buffer that exceeds one year of operating cash burn at the current run rate and provides ample runway to fund R&D, sales expansion, and potential M&A without dilutive financing. More importantly, the trajectory of key efficiency metrics is improving: Adjusted EBITDA loss narrowed from -$13.0 million in Q1 2025 to -$5.1 million in Q1 2026, driven by operating leverage as revenue grew 36% in core test volumes while total operating expenses decreased 11.8% year-over-year to $102.1 million. This improvement occurred despite increased investment in salesforce expansion (headcount growth supporting higher personnel costs in SG&A) and lab capacity (higher depreciation from facility investments), indicating that the business is successfully scaling without proportional cost inflation. The gross margin expansion from 49.2% in Q1 2025 to 72.8% in Q1 2026—despite lapping a one-time $20.1 million accelerated amortization benefit in the prior year—reflects genuine operational improvement in lab efficiency and scale, as evidenced by the stable adjusted gross margin of 75.6% (down only slightly from 81.2% in Q1 2025 due to higher variable costs from volume growth). This combination of rising margins, falling cash burn relative to revenue, and a strong balance sheet suggests the company is closer to sustainable profitability and cash flow positivity than current losses imply, with the potential to reinvest excess cash into high-return initiatives like Advanced ADTx commercialization or bolt-on acquisitions in adjacent diagnostic areas—moves that could significantly enhance long-term value creation beyond organic growth expectations.

▼ Bear case

Castle Biosciences, Inc. faces significant near-term revenue growth headwinds due to the maturation of its DecisionDx-Melanoma franchise, which is showing signs of deceleration that management is downplaying by anchoring expectations to an artificially low base from prior-year SCC revenue exclusion. While the company reported 16% year-over-year growth in DecisionDx-Melanoma test reports in Q1 2026 and reiterated mid-to-high single-digit full-year growth expectations, this performance must be viewed in context: Q1 2025 was an unusually weak comparable period due to the absence of DecisionDx-SCC and ID Genetics revenue, which the company excluded from its growth calculation to arrive at a 42% adjusted growth figure. This exclusion masks the underlying trend—when including all revenue streams, total revenue actually declined year-over-year from $87.988 million in Q1 2025 to $83.679 million in Q1 2026, a 4.9% drop—indicating that the melanoma test’s growth is not sufficiently offsetting declines elsewhere. Furthermore, management’s expectation of mid-to-high single-digit volume growth for the full year implies a significant sequential slowdown from Q1’s 16% surge, suggesting the early-quarter strength was driven by temporary factors such as delayed procedures or strong comps in specific regions, not sustainable demand acceleration. The reliance on anecdotal evidence like “record months” in March and April—without providing full-quarter visibility into May or June trends—raises concerns about whether the momentum can be maintained, especially as lapping the strong Q1 2026 performance will make year-over-year comparisons increasingly difficult in subsequent quarters. This deceleration risk is compounded by the limited upside from pricing, as the company has not indicated any meaningful average selling price increases, leaving volume growth as the sole lever for melanoma-driven revenue expansion in a market that may be nearing saturation in key dermatology accounts.
The reimbursement pathway for Advanced ADTx remains highly uncertain and underdeveloped, creating a material risk that the test fails to achieve meaningful commercial scale despite promising clinical data, a scenario management acknowledges only vaguely by referencing “traditional reimbursement” and “RCM clarity” by end of Q3 2026 without providing concrete milestones or payer commitments. While the MedTech Breakthrough award and validation studies show biological and clinical utility, the company has not disclosed any progress on securing coverage policies from major private payers or Medicare Administrative Contractors (MACs), nor has it outlined a clear strategy for overcoming the typical barriers to adoption in inflammatory skin disease, where payer skepticism toward molecular diagnostics is historically high due to concerns over cost-effectiveness and lack of outcomes-based reimbursement models. The absence of any discussion about health economics outcomes research (HEOR), real-world evidence generation beyond the initial validation study, or engagements with formulary committees suggests the commercialization effort is still in an early, preclinical phase despite the test being available since 2025. Without reimbursement, adoption will remain confined to cash-pay or limited-access settings, severely limiting volume potential—especially given that atopic dermatitis patients are often younger and may have higher out-of-pocket sensitivity. Management’s hint at alternative revenue models like partnerships with commercial companies to “shift share” is speculative and undefined, offering no near-term visibility into monetization. This ambiguity creates a significant risk that Advanced ADTx remains a niche, low-volume offering for years, failing to materialize as the midterm growth driver investors may be anticipating based on its innovative profile, and instead becoming a persistent drag on R&D and SG&A expenses without commensurate revenue return.
Castle Biosciences, Inc.’s gross margin expansion is vulnerable to reversal due to rising input costs and operational inefficiencies tied to rapid scale-up, a risk that is being overlooked because management attributes margin improvements solely to the lapping of a one-time amortization event while ignoring deteriorating trends in core profitability metrics. Although GAAP gross margin rose to 72.8% in Q1 2026 from 49.2% in Q1 2025, the adjusted gross margin—which strips out the distorting effect of the prior-year accelerated amortization and revenue adjustments—declined from 81.2% to 75.6% year-over-year, signaling that the underlying profitability of the test processing business is worsening despite higher volumes. This decline is driven by increasing cost of sales, which rose 25% year-over-year to $20.5 million due to higher lab supplies, lab services, personnel, and depreciation—all directly tied to scaling test volumes without commensurate efficiency gains. The company’s investment in expanding its Phoenix lab capacity, while framed as forward-looking, introduces fixed cost leverage that could depress margins if volume growth fails to keep pace, particularly in the melanoma franchise where growth is expected to slow. Additionally, rising SG&A expenses—up 11.2% to $64.9 million—reflect aggressive headcount expansion in sales and administrative functions that may not be yielding proportional returns, as evidenced by the sequential decline in TissueCypher volumes and the lack of transparency on sales productivity metrics like tests per rep or conversion rates. If the company continues to invest ahead of demand without clear evidence of improving operating leverage—as seen in the stagnant adjusted EBITDA margin despite revenue growth—it risks entering a phase of margin compression where fixed costs outpace revenue accumulation, undermining the financial flexibility needed to fund long-term initiatives and potentially triggering downward revisions to profitability expectations.

Castle Biosciences, Inc. faces significant near-term revenue growth headwinds due to the maturation of its DecisionDx-Melanoma franchise, which is showing signs of deceleration that management is downplaying by anchoring expectations to an artificially low base from prior-year SCC revenue exclusion. While the company reported 16% year-over-year growth in DecisionDx-Melanoma test reports in Q1 2026 and reiterated mid-to-high single-digit full-year growth expectations, this performance must be viewed in context: Q1 2025 was an unusually weak comparable period due to the absence of DecisionDx-SCC and ID Genetics revenue, which the company excluded from its growth calculation to arrive at a 42% adjusted growth figure. This exclusion masks the underlying trend—when including all revenue streams, total revenue actually declined year-over-year from $87.988 million in Q1 2025 to $83.679 million in Q1 2026, a 4.9% drop—indicating that the melanoma test’s growth is not sufficiently offsetting declines elsewhere. Furthermore, management’s expectation of mid-to-high single-digit volume growth for the full year implies a significant sequential slowdown from Q1’s 16% surge, suggesting the early-quarter strength was driven by temporary factors such as delayed procedures or strong comps in specific regions, not sustainable demand acceleration. The reliance on anecdotal evidence like “record months” in March and April—without providing full-quarter visibility into May or June trends—raises concerns about whether the momentum can be maintained, especially as lapping the strong Q1 2026 performance will make year-over-year comparisons increasingly difficult in subsequent quarters. This deceleration risk is compounded by the limited upside from pricing, as the company has not indicated any meaningful average selling price increases, leaving volume growth as the sole lever for melanoma-driven revenue expansion in a market that may be nearing saturation in key dermatology accounts.
The reimbursement pathway for Advanced ADTx remains highly uncertain and underdeveloped, creating a material risk that the test fails to achieve meaningful commercial scale despite promising clinical data, a scenario management acknowledges only vaguely by referencing “traditional reimbursement” and “RCM clarity” by end of Q3 2026 without providing concrete milestones or payer commitments. While the MedTech Breakthrough award and validation studies show biological and clinical utility, the company has not disclosed any progress on securing coverage policies from major private payers or Medicare Administrative Contractors (MACs), nor has it outlined a clear strategy for overcoming the typical barriers to adoption in inflammatory skin disease, where payer skepticism toward molecular diagnostics is historically high due to concerns over cost-effectiveness and lack of outcomes-based reimbursement models. The absence of any discussion about health economics outcomes research (HEOR), real-world evidence generation beyond the initial validation study, or engagements with formulary committees suggests the commercialization effort is still in an early, preclinical phase despite the test being available since 2025. Without reimbursement, adoption will remain confined to cash-pay or limited-access settings, severely limiting volume potential—especially given that atopic dermatitis patients are often younger and may have higher out-of-pocket sensitivity. Management’s hint at alternative revenue models like partnerships with commercial companies to “shift share” is speculative and undefined, offering no near-term visibility into monetization. This ambiguity creates a significant risk that Advanced ADTx remains a niche, low-volume offering for years, failing to materialize as the midterm growth driver investors may be anticipating based on its innovative profile, and instead becoming a persistent drag on R&D and SG&A expenses without commensurate revenue return.
Castle Biosciences, Inc.’s gross margin expansion is vulnerable to reversal due to rising input costs and operational inefficiencies tied to rapid scale-up, a risk that is being overlooked because management attributes margin improvements solely to the lapping of a one-time amortization event while ignoring deteriorating trends in core profitability metrics. Although GAAP gross margin rose to 72.8% in Q1 2026 from 49.2% in Q1 2025, the adjusted gross margin—which strips out the distorting effect of the prior-year accelerated amortization and revenue adjustments—declined from 81.2% to 75.6% year-over-year, signaling that the underlying profitability of the test processing business is worsening despite higher volumes. This decline is driven by increasing cost of sales, which rose 25% year-over-year to $20.5 million due to higher lab supplies, lab services, personnel, and depreciation—all directly tied to scaling test volumes without commensurate efficiency gains. The company’s investment in expanding its Phoenix lab capacity, while framed as forward-looking, introduces fixed cost leverage that could depress margins if volume growth fails to keep pace, particularly in the melanoma franchise where growth is expected to slow. Additionally, rising SG&A expenses—up 11.2% to $64.9 million—reflect aggressive headcount expansion in sales and administrative functions that may not be yielding proportional returns, as evidenced by the sequential decline in TissueCypher volumes and the lack of transparency on sales productivity metrics like tests per rep or conversion rates. If the company continues to invest ahead of demand without clear evidence of improving operating leverage—as seen in the stagnant adjusted EBITDA margin despite revenue growth—it risks entering a phase of margin compression where fixed costs outpace revenue accumulation, undermining the financial flexibility needed to fund long-term initiatives and potentially triggering downward revisions to profitability expectations.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password